avateramedical GmbH announced the successful completion of the CE conformity assessment procedure for its avatera system for robot-assisted, minimally invasive surgery. All four components of the system – the surgical robot and control unit, the instruments, the endoscopes and the sterile components – can now carry the CE mark. This means that avatera is now approved in the European Economic Area for minimally invasive laparoscopy (“key hole surgery”), to this point primarily used in gynecology and urology.
The avatera system was developed based on current standards in robot-assisted surgery and optimized in close cooperation with future users – including surgeons and surgical teams – in terms of cost, quality, comfort and reliability. avatera’s unique single-use concept for instruments and sterile components guarantees functional, reliable instruments for every surgical procedure, reduces the risk of contamination and associated patient infections, and avoids the cleaning and sterilization necessary with reusable instruments. Compared to classical laparoscopy, the success of robot-assisted surgery is based on the high level of comfort, precision and dexterity of the instruments. With its open design and low noise level, the avatera system also enables smooth communication in the operating room.
“The successful completion of the CE conformity assessment is an important milestone in our young history,” commented Dr. Hubertus von Gruenberg, co-founder and CEO of the avateramedical group. “We are very proud to offer our ‘German Robot’, which is developed and produced in the two Thuringian sites of the Company – Jena and Ilmenau – as a competitive solution in this strongly growing market. In the next step, we will introduce the avatera system to clinical practice.” At the same time, avateramedical’s management announced its strategic plan to build one of the most modern and largest production facilities for medical robotics in Germany in 2020 to support increased demand anticipated over the next five years. “We are confident in our plan to launch avatera in 2020, aspiring to significantly improve the uptake and access to robot-assisted surgery in Europe,” concluded Dr. von Gruenberg.
The global market for surgical robots currently stands at USD 4.5 billion with experts estimating growth to USD 13 billion by 2025.2 Current statistics underpin this growth potential with about 8.5 robotic systems (also called telemanipulator systems) available per 1 million inhabitants in the U.S. compared to only 1.0 surgical robots per 1 million inhabitants in Europe. With an ageing population, increasing demands on hospital efficiency and the growing need of surgeons and patients for better technologies, robotic surgery could soon become the gold standard in European hospitals.
Source: avateramedical GmbH